Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early

On October 21, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, reported that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS) (Press release, Merck & Co, OCT 21, 2016, View Source [SID1234515943]). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "We look forward to sharing the findings from this study with the medical community and with regulatory authorities around the world."

The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies involving patients with advanced urothelial cancer. Results from KEYNOTE-045 will be presented at an upcoming medical meeting.

The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including nearly 200 trials that combine KEYTRUDA with other cancer treatments. For genitourinary cancers, Merck has the largest immuno-oncology clinical development program in bladder cancer, with 27 trials underway involving KEYTRUDA as monotherapy and in combination, including four registration-enabling studies.

About KEYNOTE-045

KEYNOTE-045 is a randomized, pivotal, phase 3 study (ClinicalTrials.gov, NCT02256436) evaluating KEYTRUDA monotherapy compared to investigator-choice chemotherapy (paclitaxel, docetaxel, vinflunine) in the treatment of patients with metastatic or locally advanced or unresectable (inoperable) urothelial cancer that has recurred or progressed following platinum-based chemotherapy. The co-primary endpoints are overall survival (OS) and progression-free survival (PFS); secondary endpoints are overall response rate (ORR), duration of response (DOR), and safety. The study randomized 542 patients to receive KEYTRUDA (200 mg every three weeks) or investigator-choice of paclitaxel (175 mg/m2 every three weeks), docetaxel (75 mg/m2 every three weeks), or vinflunine (320 mg/m2 every three weeks).

About Bladder Cancer

Bladder cancer begins when cells in the urinary bladder start to grow uncontrollably. As more cancer cells develop, they can form a tumor and spread to other areas of the body. Urothelial carcinoma, the most common type of bladder cancer, starts in the urothelial cells that line the inside of the bladder. In 2012, approximately 430,000 people worldwide were diagnosed with bladder cancer and 165,000 died from the disease. The incidence of bladder cancer is elevated in North America, Europe, North Africa, the Middle East, Australia and New Zealand.

About KEYTRUDA (pembrolizumab)

KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

KEYTRUDA is administered as an intravenous infusion over 30 minutes every three weeks for the approved indications. KEYTRUDA for injection is supplied in a 100 mg single use vial.

ENLIVEN Phase 3 Study of Pexidartinib in Tenosynovial Giant Cell Tumor (TGCT) Will Continue to Completion Following Enrollment Discontinuation

On October 21, 2016 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) reported that it will discontinue additional enrollment of the phase 3 ENLIVEN study of the investigational oral CSF-1R inhibitor pexidartinib (PLX3397) in tenosynovial giant cell tumor; however, the study will proceed with currently enrolled patients under a revised protocol (Press release, Daiichi Sankyo, OCT 21, 2016, View Source [SID1234515940]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!



Following review of two recently reported cases of non-fatal, serious liver toxicity, the ENLIVEN data monitoring committee (DMC) recommended that further enrollment into the study be suspended. At the time of enrollment suspension 121 patients had been randomized, five patients short of the 126 planned for full enrollment. The DMC also recommended measures to address these safety concerns while maintaining the blinded nature of the study. As a result, ENLIVEN will continue in order to evaluate its efficacy and safety endpoints.

All regulatory authorities involved in the ENLIVEN study have been notified. All patients currently enrolled in ENLIVEN are being informed about this updated safety information and will be offered the opportunity to re-consent for continued participation in the study.

"Ensuring patient safety is our first obligation and we sincerely thank all of the investigators and patients participating in this study," said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. "Upon completion of the study with currently enrolled patients, Daiichi Sankyo will conduct and report a thorough evaluation of the results and consider any and all appropriate next steps."

ENLIVEN is an ongoing global, multi-center, pivotal two-part phase 3 study evaluating pexidartinib in patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity. The first part of the study, which is the double-blind phase, is designed to evaluate the efficacy and safety of pexidartinib versus placebo. The second part of the study is a longer-term open-label study of pexidartinib.

About TGCT
Tenosynovial giant cell tumor (TGCT) – also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS) – is a rare, usually non-cancerous tumor that affects the synovium-lined joints, bursae, and tendon sheaths, resulting in swelling, pain, stiffness and reduced mobility in the affected joint or limb.1 It is estimated that TGCT has an annual incidence of 11 cases per million.2 Patients are commonly diagnosed in their 20s to 50s,and depending on the type of TGCT, women can be up to twice as likely to develop a tumor as men.3,4

Primary treatment of TGCT includes surgery to remove the tumor, but in patients with a diffuse form where it can wrap around bone, tendons, ligaments and other parts of the joint, the tumor is more difficult to remove and may require multiple surgeries or joint replacement, eventually advancing to the point where surgery is no longer an option and amputation may be considered. It is estimated that the rate of recurrence can be about 15 to 45 percent.5

About Pexidartinib
Pexidartinib is an investigational novel, oral small molecule that potently and selectively inhibits CSF-1R (colony stimulating factor-1 receptor), which is a primary growth driver of abnormal cells in the synovium that cause TGCT.

Pexidartinib has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of TGCT. Pexidartinib has also been granted Orphan Drug Designation by the FDA for the treatment of PVNS/GCT-TS and received Orphan Designation from the European Commission for the treatment of TGCT. Pexidartinib has not been approved by any regulatory authority for any use.

Pexidartinib is being evaluated in several additional potential clinical indications, including glioblastoma, ovarian, breast, colorectal, pancreatic and prostate cancer, malignant peripheral nerve sheath tumor, and pediatric cancers. It is also being investigated in combination with anti-PD-1 immunotherapy, pembrolizumab, for advanced melanoma or other solid tumors.

SOTIO and NBE Therapeutics Sign Collaboration and License Agreement for Next-Generation Antibody-Drug Conjugates

On October 20, 2016 NBE Therapeutics AG and SOTIO a.s. reported that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates (ADCs) for improved cancer therapy (Press release, NBE Therapeutics, OCT 20, 2016, View Source [SID1234573379]). Under the agreement, NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products will be based on NBE’s proprietary antibody discovery and conjugation platforms, including NBE’s Transpo-mAb antibody platform, its site-specific SMAC conjugation technology and its novel ultra-potent toxin platform. SOTIO will have global responsibility for clinical development, registration and commercialization of the ADC products.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Upon exercise of the target options, NBE will be eligible for an option exercise fee, as well as milestone payments and royalties based on global net sales of the products. In addition, NBE will be reimbursed for its R&D expenses incurred in connection with the development of the product in collaboration with SOTIO.

As part of the deal, PPF Group, the owner of SOTIO, has committed to invest CHF10m in the next financing round of NBE.

Dr Ulf Grawunder, CEO of NBE Therapeutics commented: "We are excited about entering a strategic collaboration with SOTIO. This partnership validates our ADC platform and will allow us to further expand our ADC product pipeline. SOTIO’s proven clinical development expertise will help us to develop our ADC platform to the next level."

Ladislav Bartonicek, CEO of SOTIO and shareholder of PPF commented: "NBE’s product platform addresses the key issues of today’s antibody-drug conjugates. With the very strong preclinical data generated by NBE that show superiority in terms of potency, safety and product homogeneity, as well as strong immunotherapeutic effects, this platform has the potential to provide new superior treatment options for cancer patients."

Dilaforette changes name to Modus Therapeutics and announces intention to conduct an Initial Public Offering

On October 20, 2016 Dilaforette Holding AB, a clinical-stage drug development company, reported its name change to Modus Therapeutics Holding AB and its intention to undertake an Initial Public Offering ("IPO") (Press release, Modus Therapeutics Holding, OCT 20, 2016, View Source [SID1234517242]). A rights issue is planned in connection with the IPO in order to finance the further clinical development of the Company’s lead candidate sevuparin for the treatment of sickle cell disease ("SCD").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting on today’s announcement, Christina Herder, CEO of Modus Therapeutics, said: "Modus Therapeutics is entering an exciting phase with the opportunity to develop sevuparin in sickle cell disease in two separate uses based on promising data, recently published in the British Journal of Haematology (Telen et al, August, 2016). Sevuparin is now in Phase II clinical trials and we have a clear objective to advance this promising candidate through these trials to establish clinical proof of concept in both a hospital and a home setting over the next years."

Viktor Drvota, Chief Investment Officer at Karolinska Development and recently elected as new member of Modus Therapeutics Board of Directors, said: "Modus Therapeutics has established a strong basis with sevuparin in SCD from which to advance to the next value inflection milestones. The proposed IPO would provide further support to the Company to build on its encouraging clinical findings with sevuparin and develop a potentially best- and first-in-class treatment for SCD patients with few effective therapeutic options. Modus Therapeutics is one of several companies in our portfolio that are expected to deliver important milestones in the coming years and we are delighted with how this portfolio is maturing."

For further information: Christina Herder, CEO, Tel: + 46 70 374 71 56, [email protected]

David Dible or Pip Batty, Citigate Dewe Rogerson, Tel: +44 207 282 2049/1022, [email protected]

Cantargia to Present New Data from Preclinical Studies with CAN04 in Non-Small Cell Lung Cancer

On October 20, 2016 Cantargia AB ("Cantargia") reported that it will be presenting new data at the Protein & Antibody Engineering Summit ("PEGS (View Source)"), an international scientific conference to be held in Lisbon, Portugal, from October 31st to November 4th 2016 (Press release, Cantargia, OCT 20, 2016, View Source [SID1234515952]). The company will be presenting data from preclinical studies in non-small cell lung cancer, where the product candidate CAN04, a humanised antibody against the IL1RAP target molecule, has been investigated. The presentation will take place on October 31st 2016.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With the ambition of developing a new cancer therapy, Cantargia has developed a fully humanised antibody, CAN04, which binds with high affinity to Interleukin-1 Receptor Associated Protein ("IL1RAP"). The antibody blocks signalling from the inflammatory cytokine IL-1, which in turn reduces signals that promote tumour growth and survival. Cantargia has previously shown that antibodies against IL1RAP can stimulate killing of tumour cells in various preclinical PDX-models of leukemia.

In the new study Cantargia shows that high levels of IL1RAP are expressed also in several different solid tumours, including non-small cell lung cancer. CAN04 treatment of various solid tumour cell lines with IL1RAP on the cell surface led to a reduced secretion of the inflammatory and tumorigenic cytokines IL-6 and IL-8. CAN04 also stimulated cells from the immune system to directly destroy these tumour cells. In a PDX model, mice were transplanted directly with tumour cells from a patient with non-small cell lung cancer. In this model a microenvironment is developed in the tumour that is not obtained in classical cell line-based models. A statistically significant treatment effect was obtained with CAN04 in the study.

"We are very pleased to present new data on CAN04 at an important scientific conference. In addition to the documented effect in various models of non-small cell lung cancer, including a very aggressive PDX model, these results constitute an important base for continued studies of CAN04 both as monotherapy and in combination with other drugs", Göran Forsberg, CEO, says.

The poster, The CAN04 antibody targets IL1RAP and inhibits tumor growth in a PDX model for NSCLC, will be available at www.cantargia.com after the presentation.

This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 20 October 2016, at 08.30.